“The current problem has uncovered some structural weaknesses inside the EU’s medicines supply chain in addition to a significant dependence on non-EU countries for active pharmaceutical ingredients,” Kyriakides claimed. She advised that supply chain concerns be addressed within an EU pharmaceutical strategy anticipated to get launched by the top from https://www.rilife.co/pharmaceutical-solvents-supplier-in-india-2/